Yan Lv

592 total citations
24 papers, 392 citations indexed

About

Yan Lv is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yan Lv has authored 24 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Yan Lv's work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), MicroRNA in disease regulation (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Yan Lv is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (3 papers), MicroRNA in disease regulation (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Yan Lv collaborates with scholars based in China, United States and Hong Kong. Yan Lv's co-authors include Haijun Zhang, Meng Cao, Xueting Cai, Ling Weng, Haoying Huang, Qingyun Wei, Xuan Han, Wei Qin, Peng Cao and Mengyuan Li and has published in prestigious journals such as Journal of Medicinal Chemistry, Remote Sensing and Molecular Therapy.

In The Last Decade

Yan Lv

22 papers receiving 382 citations

Peers

Countries citing papers authored by Yan Lv

Since Specialization

Citations

This map shows the geographic impact of Yan Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Lv more than expected).

Fields of papers citing papers by Yan Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Lv. The network helps show where Yan Lv may publish in the future.

Co-authorship network of co-authors of Yan Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Lv. A scholar is included among the top collaborators of Yan Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Lv. Yan Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning combined with omics-based approaches reveals T-lymphocyte cellular fate imbalance in abdominal aortic aneurysm 2025 ·BMC Biology ·Demin Li, Ge Zhang, (unknown), Chang Cao, Xuesong He, Yan Lv, (unknown), Yujia Wang, (unknown), Yiling Cao, Yang Yu, (unknown), (unknown), Guo-Ping Shi, Xiaolin Cui, Jinying Zhang, Junnan Tang	0
2	Hyperspectral Band Selection for Crop Identification and Mapping of Agriculture 2025 ·Remote Sensing ·(unknown), (unknown), Laijun Lu, (unknown), Jianyu Huang, Lin Pan, Yan Lv, (unknown), Chen Yang	2
3	GDHS: An efficient hybrid sampling method for multi-class imbalanced data classification 2025 ·Neurocomputing ·Yuanting Yan, Yan Lv, S. G. Han, (unknown), Peng Zhou	1
4	Development and validation of multi-sequence magnetic resonance imaging radiomics models for predicting tumor response to radiotherapy in locally advanced non-small cell lung cancer 2025 ·Journal of Thoracic Disease ·(unknown), Yan Lv, (unknown), (unknown), Helong Wang, Songliu Hu, Baptiste Abbar, Jianyu Xu	1
5	Study of the mechanism by which Xiaoyan decoction combined with E7449 regulates tumorigenesis in lung adenocarcinoma 2024 ·Journal of Cellular and Molecular Medicine ·(unknown), Yanyan Han, Lili Gu, Shan Gao, Yan Lv, Chong Li	2
6	Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis 2024 ·Frontiers in Oncology ·Ke Chen, Yanyu Zhang, (unknown), (unknown), Xinyue Yu, (unknown), Yumeng Li, (unknown), Yi Chen, (unknown), Weiyi Liu, Yan Lv, (unknown), (unknown)	0
7	Active learning concerning sampling cost for enhancing AI-enabled building energy system modeling 2024 ·Advances in Applied Energy ·Ao Li, Fu Xiao, Ziwei Xiao, Rui Yan, Anbang Li, Yan Lv, Bing Su	6
8	Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment 2023 ·Journal of Experimental & Clinical Cancer Research ·Yan Lv, Mengyuan Li, Ling Weng, Haoying Huang, (unknown), (unknown), Qingyun Wei, (unknown), Wei Qin, Ke Rui, Xuan Han, Weiwei Fan, Xueting Cai, Peng Cao, Meng Cao	27
9	Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer 2023 ·Journal of Nanobiotechnology ·Haoying Huang, Xiaohan Yi, Qingyun Wei, Mengyuan Li, Xueting Cai, Yan Lv, Ling Weng, (unknown), Weiwei Fan, (unknown), (unknown), (unknown), (unknown), Meng Cao, Jing Chen, Peng Cao	36
10	Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer 2022 ·Journal of Medicinal Chemistry ·Dongdong Luo, Xiaochun Liu, (unknown), Zhikun Guo, Yan Lv, (unknown), Xiaoyan Wang, Shu‐Xiang Cui, Shengbiao Wan, Xian‐Jun Qu, Ximing Xu, Xiaoyang Li	6
11	Fast support vector classifier with generalization-memorization kernel 2022 ·Procedia Computer Science ·(unknown), Yan Lv, (unknown), Zhen Wang, (unknown)	2
12	Potential probiotics Lactobacillus casei K11 combined with plant extracts reduce markers of type 2 diabetes mellitus in mice 2021 ·Journal of Applied Microbiology ·(unknown), Lu Bai, (unknown), Xihong Zhou, Xi Liang, Yan Lv, Huaxi Yi, Hui Zhou, (unknown), Pimin Gong, (unknown), Lanwei Zhang	9
13	Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment 2021 ·Molecular Therapy ·Xuan Han, Wei Qin, Yan Lv, Ling Weng, Haoying Huang, Qingyun Wei, Mengyuan Li, (unknown), Di Hua, Xueting Cai, Meng Cao, Peng Cao	105
14	Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study 2021 ·ESMO Open ·Mingming Li, Xue Hou, Lie Zheng, Yutong Ma, (unknown), Yan Lv, Jianxu Chen, Wei Zheng, Yang Shao, Yonggao Mou, (unknown)	13
15	Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report 2021 ·Annals of Palliative Medicine ·Ke Wang, Haoyang Wang, Yan Lv, Huiling Liu, Jiabin Liu, Ying Zhang	6
16	Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer 2021 ·European Journal of Medicinal Chemistry ·Dongdong Luo, Yuhang Zhang, Shuang Yang, (unknown), Yan Lv, Zhikun Guo, Xiaochun Liu, (unknown), Shuai Liu, Wenyu Wang, Shu‐Xiang Cui, Xian‐Jun Qu, Shengbiao Wan	14
17	Effect of Non-alcoholic Fatty Liver Disease on the Risk of Synchronous Liver Metastasis: Analysis of 451 Consecutive Patients of Newly Diagnosed Colorectal Cancer 2020 ·Frontiers in Oncology ·Yan Lv, Haijun Zhang	22
18	The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer 2019 ·Expert Review of Gastroenterology & Hepatology ·Yan Lv, Nishant Patel, Haijun Zhang	23
19	XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway 2018 ·Oncology Letters ·Chong Li, Xu Zheng, Yanyan Han, Yan Lv, Lan Fu, Jie Zhao	45
20	Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer 2013 ·Medical Oncology ·Min Dong, Xiang‐Bo Wan, (unknown), Wei Li, (unknown), Tiantian Wang, Yan Lv, Xing Li, Zhan‐Hong Chen, Jie Chen, Qu Lin, (unknown), (unknown), Quentin Liu, Xiang Wu	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact